What analysts say:
- Buy, sell, or hold?: Analysts strongly back Covance, with eight of 15 rating it a buy and the remainder rating it a hold. Analysts like Covance better than competitor Pharmaceutical Product Development overall. Wall Street has warmed to the stock over the past three months, with analysts increasing their endorsement from hold to moderate buy.
- Revenue forecasts: On average, analysts predict $521.3 million in revenue this quarter. That would represent a rise of 9.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.70 per share. Estimates range from $0.69 to $0.72.
What our community says:
CAPS All-Stars are solidly behind the stock with 99.2% giving it an "outperform" rating. The community at large agrees with the All-Stars with 97.6% granting it a rating of "outperform." Fools are bullish on Covance, though the message boards have been quiet lately with only 95 posts in the past 30 days. Even with a robust four out of five stars, Covance's CAPS rating falls a little short of the community's upbeat outlook.
Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Covance now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.